Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. reports developments in sleep health, respiratory care and home healthcare technology. The company supplies sleep apnea and breathing-care devices, including CPAP platforms such as AirSense 11, and supports them with cloud-connected software, AI-enabled digital health tools and patient data applications used in out-of-hospital care.
Recurring updates include quarterly operating results, demand trends for sleep and respiratory care products, FDA-cleared digital medical devices such as Smart Comfort, supply-chain and distribution capacity, shareholder returns, executive leadership changes and investor conference presentations. ResMed’s announcements also reflect its NYSE-listed common stock and ASX-traded presence.
ResMed (NYSE: RMD) plans to report its financial and operational results for Q1 FY 2021 on October 29, 2020, after market close. A management webcast will follow to discuss these results and additional forward-looking information. The earnings call is scheduled for 1:30 p.m. PDT / 4:30 p.m. EDT and will be accessible through ResMed's investor relations website.
The earnings call replay will be available for two weeks following the event. ResMed specializes in innovative health solutions for chronic diseases, enhancing care quality while reducing healthcare costs globally.
VIDA Diagnostics has appointed Karen Drexler to its board of directors, enhancing its leadership in digital health technology amid the ongoing COVID-19 pandemic. Drexler, an experienced entrepreneur with a background in digital health and established accolades, aims to support VIDA's mission to modernize lung and respiratory care. Her appointment is expected to bolster market expansion and innovation in AI-powered lung intelligence solutions, aligning with the heightened focus on lung health and the rising demand for advanced medical technologies.